Developed RenMab Mouse, a fully human antibody mouse model; Closed D-round funding in July
Beijing and Haimen Phase II animal facility is under construction
Received C-round funding from CMB International Capital Corporation Limited, SDIC Venture Capital, 3E Bioventures, Cowin Capital Group and Oriza Holdings
Boston and Shanghai sites opened for business
Haimen Animal Center began operations; AAALAC accreditation earned; Antibody Discovery Service Platform established; B-NDG™ and a comprehensive variety of humanized immune checkpoint mice were supplied to clients
Established preclinical services platform; Raised B-round funding from SDIC Venture Capital and BioVeda China Fund
Developed B-NDG™ mice (highly immune deficient) and B-hPD-1, the first humanized immune-checkpoint mouse model
1st customized gene targeted mouse line delivered
Beijng Biocytogen Co., Ltd (Headquarters) established
Founded in Worcester, MA, USA
